期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 18, 期 1, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2021.1875762
关键词
Patient-reported outcomes; comparative effectiveness; electronic PRO; health technology assessment; clinical outcomes assessments; health-related quality of life; qualitative research; PRO instruments; public health benefit; vaccines
资金
- GlaxoSmithKline Biologicals SA
The past century has seen exponential growth in the development and demand for effective vaccines. Regulatory agencies are now focusing more on understanding patient perception and experience. Various research methods utilizing patient-reported outcomes (PROs) have been widely used in the vaccine field, with additional advantages observed through electronic data capture.
The development and demand for effective vaccines have witnessed an exponential growth over the last century. In the meantime, the vaccine market involves more knowledgeable stakeholders, with a shift in emphasis by regulatory agencies on understanding the patient perception and experience. The Food and Drug Administration's publication of the patient-reported outcomes (PRO) guidance has elevated the discipline of PROs and has resulted in a transition from clinician reports of patient outcomes to PROs. This review reports various research methods, which utilize PROs, including qualitative and quantitative research, clinical trials, and patient preference studies. With the advancement of electronic PRO data capture, additional advantages of PROs are being observed and utilized (e.g. as a trigger for clinical endpoints). We discuss uses and advantages of including PROs into the clinical trial program to improve efficiencies, clinical relevance and overall validity of the program in the vaccine field. (See Plain Language Summary)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据